In a study of Hong Kong Chinese cohort consisted of 310 female and male breast or ovarian cancer patients with BRCA mutation rate of 13.9%25, BOADICEA appeared to be the most accurate in combined BRCA1/2 mutation prediction among the five tested models, while BRCAPRO better predicted mutations of BRCA1 alone. This evidence concerns the gene BRCA1 and ovarian carcinoma.